查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1881591

重症肌无力治疗市场－全球产业规模、份额、趋势、机会和预测，依治疗类型、最终用途、地区和竞争格局划分，2020-2030年预测

Myasthenia Gravis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By End Use, Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024年全球重症肌无力治疗市场规模为23.2亿美元，预计2030年将以7.44%的复合年增长率成长至35.7亿美元。重症肌无力治疗涵盖旨在控制这种慢性自体免疫神经肌肉疾病的药物介入。此疾病的特征是由于神经肌肉通讯受损而导致不同程度的骨骼肌无力和疲劳。市场成长的主要驱动因素是该疾病在全球范围内的盛行率不断上升以及诊断能力的提高，从而实现了早期发现。

市场概览
预测期 2026-2030
2024年市场规模 23.2亿美元
2030年市场规模 35.7亿美元
2025-2030年复合年增长率 7.44%
成长最快的细分市场 医院和诊所
最大的市场 北美洲

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球重症肌无力治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依治疗类型（胆碱酯酶抑制剂、慢性免疫调节剂、单株抗体、快速免疫疗法、胸腺切除、其他）
    • 依最终用途（医院和诊所、门诊手术中心、其他）
    • 按地区
    • 按公司（2024 年）
  • 市场地图

第六章：北美重症肌无力治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第七章：欧洲重症肌无力治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区重症肌无力治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲重症肌无力治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东和非洲：国家分析
    • 沙乌地阿拉伯
    • 阿联酋
    • 南非

第十章：南美洲重症肌无力治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章：市场动态

  • 司机
  • 挑战

第十二章：市场趋势与发展

  • 併购（如有）
  • 产品发布（如有）
  • 最新进展

第十三章：全球重症肌无力治疗市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商议价能力
  • 顾客的力量
  • 替代产品的威胁

第十五章：竞争格局

  • Alexion Pharmaceutical Inc.
  • Grifols International, SA
  • Avadel Pharmaceuticals, Plc.
  • Novartis AG
  • Pfizer, Inc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc.
  • Bausch Health Companies Inc.

第十六章：策略建议

第17章调查会社について・免责事项

简介目录
Product Code: 22106

The Global Myasthenia Gravis Treatment Market, valued at USD 2.32 Billion in 2024, is projected to experience a CAGR of 7.44% to reach USD 3.57 Billion by 2030. Myasthenia Gravis treatment encompasses pharmaceutical interventions designed to manage this chronic autoimmune neuromuscular disorder, characterized by varying degrees of skeletal muscle weakness and fatigue resulting from impaired nerve-muscle communication. Market growth is primarily driven by the increasing prevalence of the condition globally and enhanced diagnostic capabilities that lead to earlier detection.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.32 Billion
Market Size 2030USD 3.57 Billion
CAGR 2025-20307.44%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

Key Market Drivers

Rising global prevalence of Myasthenia Gravis significantly fuels the demand for effective treatments. The increasing number of diagnosed cases worldwide broadens the patient pool requiring chronic disease management, necessitating a wider array of therapeutic options and greater accessibility to existing ones. This trend is driven by improved diagnostic capabilities and enhanced disease awareness among healthcare professionals. For instance, according to a systematic review published in Neuroepidemiology, in October 2024, the mean prevalence rate of Myasthenia Gravis increased from 97.5 cases per million person-years during 1967-2007 to 220.1 cases per million person-years in the 2008-2022 timeframe.

Key Market Challenges

The substantial cost associated with advanced therapies, particularly biologics, presents a significant impediment to the growth of the Global Myasthenia Gravis Treatment Market. These high expenditures directly constrain patient access and adoption, especially in regions with developing healthcare infrastructure or stringent reimbursement policies. Healthcare systems and individual patients often struggle to absorb the ongoing financial burden of these advanced treatments, leading to delays in initiation or discontinuation of therapy.

Key Market Trends

The global Myasthenia Gravis treatment market is significantly influenced by the expansion of personalized medicine approaches. This trend emphasizes tailoring treatments to individual patient profiles, moving beyond a one-size-fits-all strategy to improve efficacy and minimize adverse effects. The increasing understanding of disease heterogeneity and the identification of specific biomarkers are crucial to this evolution. According to the Pharmaceutical Research and Manufacturers of America (PhRMA) 2024 Special 301 Submission, PhRMA member companies invested nearly $101 billion in research and development (R&D) in 2022 alone, underscoring the extensive financial commitment towards innovative and personalized therapeutic solutions.

Key Market Players

  • Alexion Pharmaceutical Inc.
  • Grifols International, S.A.
  • Avadel Pharmaceuticals, Plc.
  • Novartis AG
  • Pfizer, Inc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc.
  • Bausch Health Companies Inc.

Report Scope:

In this report, the Global Myasthenia Gravis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Myasthenia Gravis Treatment Market, By Treatment Type:

  • CholinesteraseInhibitors
  • Chronic Immunomodulators
  • Monoclonal Antibodies
  • Rapid Immunotherapies
  • Thymectomy
  • Others

Myasthenia Gravis Treatment Market, By End use:

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Others

Myasthenia Gravis Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Myasthenia Gravis Treatment Market.

Available Customizations:

Global Myasthenia Gravis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Myasthenia Gravis Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (CholinesteraseInhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy, Others)
    • 5.2.2. By End use (Hospitals & Clinics, Ambulatory Surgical Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Myasthenia Gravis Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By End use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Myasthenia Gravis Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By End use
    • 6.3.2. Canada Myasthenia Gravis Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By End use
    • 6.3.3. Mexico Myasthenia Gravis Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By End use

7. Europe Myasthenia Gravis Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By End use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Myasthenia Gravis Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By End use
    • 7.3.2. France Myasthenia Gravis Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By End use
    • 7.3.3. United Kingdom Myasthenia Gravis Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By End use
    • 7.3.4. Italy Myasthenia Gravis Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By End use
    • 7.3.5. Spain Myasthenia Gravis Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By End use

8. Asia Pacific Myasthenia Gravis Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By End use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Myasthenia Gravis Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By End use
    • 8.3.2. India Myasthenia Gravis Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By End use
    • 8.3.3. Japan Myasthenia Gravis Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By End use
    • 8.3.4. South Korea Myasthenia Gravis Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Type
        • 8.3.4.2.2. By End use
    • 8.3.5. Australia Myasthenia Gravis Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Type
        • 8.3.5.2.2. By End use

9. Middle East & Africa Myasthenia Gravis Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By End use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Myasthenia Gravis Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By End use
    • 9.3.2. UAE Myasthenia Gravis Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By End use
    • 9.3.3. South Africa Myasthenia Gravis Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By End use

10. South America Myasthenia Gravis Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By End use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Myasthenia Gravis Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By End use
    • 10.3.2. Colombia Myasthenia Gravis Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By End use
    • 10.3.3. Argentina Myasthenia Gravis Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By End use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Myasthenia Gravis Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Alexion Pharmaceutical Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Grifols International, S.A.
  • 15.3. Avadel Pharmaceuticals, Plc.
  • 15.4. Novartis AG
  • 15.5. Pfizer, Inc.
  • 15.6. AbbVie Inc.
  • 15.7. F. Hoffmann-La Roche Ltd.
  • 15.8. GlaxoSmithKline plc.
  • 15.9. Bausch Health Companies Inc.

16. Strategic Recommendations

17. About Us & Disclaimer